余文颖，1984年6月生。博士、副研究员、博士生导师，美国药学会会员，美国化学会会员。2002年至2006年就读于中国药科大学国家生命科学与技术人才培养基地班，“4+2”本硕连读。2006年免试推荐为中国药科大学药物化学硕士研究生，2008年获理学硕士学位。同年获美国俄亥俄州立大学（The Ohio State University）药学院全额奖学金资助留学，2013年获俄亥俄州立大学药物化学博士学位（PhD.），并获得JACK. L. BEAL优秀博士生奖学金。2013年底作为海外人才引进于中国药科大学药物科学研究院国家重点实验室。2016年晋升为特聘副研究员；2017年晋升为副研究员。
主要研究方向：1. 计算机辅助药物设计（CADD）新方法的设计和研究；2. 基于STAT3蛋白靶点的抗肿瘤药物研究；3. 基于活性天然化合物的合成方法研究和药物研究。4.针对IL-6/JAK/STAT信号通路的药物研究。
从事科研工作以来，紧密结合药物化学、计算化学、合成化学、生物统计学、药理学等交叉专业背景的优势，设计和发现了针对肿瘤靶点“蛋白-蛋白”相互作用的药物活性分子，取得了一系列标志性、创新性的重要研究成果。其中在药物化学领域一区杂志Journal of Medicinal Chemistry等发表多篇文章。授权美国专利和世界专利各1项。
作为课题负责人主持了国家自然科学基金面上项目一项，江苏省自然科学基金优秀青年项目一项，国家自然科学基金青年项目一项，江苏省自然科学基金青年项目一项，留学回国人员择优资助项目一项等，经费共计逾百万元。作为主要参与人参加了国家自然科学基金重点项目等多项基金。2014年入选江苏省双创计划“双创博士”。2015年指导的大创项目被评为国家级优秀项目。
联系方式：
邮箱：ywy@cpu.edu.cn
电话：**
代表性论文：

1.Wenying Yu, Chenglong Li, Wenda Zhang, Shanshan Li, Jia-yuh Lin, Keqin Yu, Mu Liu, Lei Yang, Jianguang Luo, Yijun Chen, Hongbin Sun, and Lingyi Kong*, Discovery of an orally selective inhibitor of signal transducer and activator of transcription 3 using advanced multiple ligand simultaneous docking, Journal of Medicinal Chemistry, 2017, 60, 2718-2731. (IF:6.3)
2.Wenying Yu, Hui Xiao, Jiayuh Lin, Chenglong Li^*, Discovery of novel STAT3 small molecule inhibitors via in silicosite-directed fragment-based drug design, Journal of Medicinal Chemistry, 2013, 56, 4402?4412 (IF: 5.5)
3.Wenda Zhang, Feiyan Liu, Chao Zhang, Jianguang Luo, Jun Luo, Wenying Yu**, and Lingyi Kong*, Near-Infrared Fluorescent Probe with Remarkable Large Stokes Shift and Favorable Water Solubility for Real-Time Tracking Leucine Aminopeptidase in Living Cells and In Vivo,Analytical Chemistry,2017, 89, 12319?12326.(IF: 6.2)
4.Jianpeng Guo¹, Wenying Yu¹**, Guiping Cai, Wenda Zhang, Shanshan Li, Jiawen Zhu, Dongmei Song, Lingyi Kong*. Discovery of new benzensulfonamide derivatives as tripedal STAT3 inhibitors, European Journal of Medicinal Chemistry,2018, 151, 752-764.(IF: 4.8)
5.Wenda Zhang, Ting Ma, Shanshan Li, Yanwei Yang, Jianpeng Guo, Wenying Yu**, Lingyi Kong*, Antagonizing STAT3 activation with benzo[b]thiophene 1, 1-dioxide based small molecules, European Journal of Medicinal Chemistry, 2017,125, 538-550. (IF: 4.8)
6.Shanshan Li, Wenda Zhang, Yanwei Yang, Ting Ma, Jianpeng Guo, Shanshan Wang, Wenying Yu**, Lingyi Kong*, Discovery of oral-available resveratrol-caffeic acid based hybrids inhibiting acetylated and phosphorylated STAT3 protein, European Journal of Medicinal Chemistry, 2016, 124, 1006-1018. (IF: 4.5)
7.Wenda Zhang, Jianpeng Guo, Shanshan Li, Ting Ma, Dingqiao Xu, Chao Han, Feiyan Liu, Wenying Yu**, Lingyi Kong*, Discovery of monocarbonyl curcumin-BTP hybrids as STAT3 inhibitors for drug-sensitive and drug-resistant breast cancer therapy, Scientific Reports, 2017,7:46352. (IF: 4.3)
8.Wenying Yu, Chenglong Li^*, Regioselective one-pot C-N coupling of substituted naphthoquinones: selective intramolecular ring fusion of sulfonamides, Tetrahedron, 2014, 70, 459-464. (IF: 2.6)
9.Wenying Yu, Chenglong Li^*, 4-Nitrophenyl N-(2-sulfamoylphenyl)-carbamate，Acta Crystallographica Section E, 2013, E69, o355
10.余文颖, 张奕华^*, 赖宜生, 接振旺, 张玉彬^*, 彭司勋, 一氧化氮供体型双水杨酸酯衍生物的合成及降血糖活性, 中国药科大学学报, 2008, 39, 4, 301-305
11.Chongqiang Zhao, Wenlong Wang, Wenying Yu, David Jou, Yina Wang, Haiyan Ma, Hui Xiao, Hua Qin, Cuntai Zhang, Jiagao Lu, Sheng Li, Chenglong Li, Jiayuh Lin, Li Lin^*, A novel small molecule STAT3 inhibitor, LY5, inhibits cell viability, colony formation, and migration colon and liver cancer cells, Oncotarget, 2016 (IF: 5.2)
12.Jin-Fang Xu, Hui-Jun Zhao, Xiao-Bing Wang, Zhong-Rui Li, Jun Luo, Ming-Hua Yang, Lei Yang, Wen-Ying Yu, He-Quan Yao, Jian-Guang Luo*, Ling-Yi Kong*, (±)-Melicolones A and B, rearranged prenylated acetophenone stereoisomers with an unusual 9-oxatricyclo[3.2.1.1^3,8]nonane core from the leaves of Melicope ptelefolia, Organic Letters, 2015, 17, 1, 146-149. (IF: 6.7)
13.YanLiu, AiguoLiu, ZhenghuXu, WenyingYu, HongWang, ChenglongLi, JiayuhLin*,XZH-5 inhibits STAT3 phosphorylation and causes apoptosis in human hepatocellular carcinoma cells, Apoptosis, 2011, 16, 5, 502-10.(IF: 4.8)
14.Hui Xiao, Hemant Kumar Bid, David Jou, Xiaojuan Wu, Wenying Yu, Chenglong Li, Peter J. Houghton, Jiayuh Lin*, A Novel Small Molecular STAT3 Inhibitor, LY5, Inhibits Cell Viability, Cell Migration, and Angiogenesis in Medulloblastoma Cells, The Journal of Biological Chemistry, 2015, 290, 3418-3429.(IF: 4.3)
15.Sai-Sai Xie, Xiaobing Wang, Neng Jiang, Wenying Yu, Kelvin D.G. Wang, Jin-Shuai Lan, Zhong-Rui Li, Ling-Yi Kong*, Multi-target tacrine-coumarin hybrids: Cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease, European Journal of Medicinal Chemistry, 2015, 95, 5, 153-165. (IF: 3.9)
16.Aiguo Liu, Yan Liu, Zhenghu Xu,Wenying Yu,Hong Wang,Chenglong Li, Jiayuh Lin*, Novel small molecule, XZH-5, inhibits constitutive and interleukin-6-induced STAT3 phosphorylation in human rhabdomyosarcoma cells, Cancer science, 2011, 102, 7, 1381-1387
17.Yang Li, Xuliang Wang, Rong Fu, Wenying Yu, Xiaoli Wang, Yisheng Lai, Sixun Peng, Yihua Zhang*, Synthesis and evaluation of nitric oxide-releasing derivatives of 3-n-butylphthalide as anti-platelet agents, Bioorganic & Medicinal Chemistry Letters, 2011, 21, 14, 4210-4214. (IF: 2.6)
18.Zi-Chen Xu, Xiao-Bing Wang, Wen-Ying Yu, Sai-Sai Xie, Su-Yi Li, Ling-Yi Kong*, Design, synthesis and biological evaluation of benzylisoquinoline derivatives as multifunctional agents against Alzheimer's disease, Bioorganic & Medicinal Chemistry Letters, 2014, 24, 10, 2368-237. (IF: 2.4)